Hematol Oncol Clin North Am. 2024 May 9:S0889-8588(24)00030-3. doi: 10.1016/j.hoc.2024.03.003. Online ahead of print.
ABSTRACT
Precursor diseases of multiple myeloma (MM) are monoclonal gammopathy of uncertain significance and smoldering MM. While it is well known that a percentage of those affected by these conditions will progress to MM, it is difficult to predict who will progress and when, and guidelines for screening for these conditions are lacking. Moreover, there are various models for risk stratification, though there are ongoing efforts to improve these models in order to predict who may benefit from treatment. Finally, there are various clinical trials, both past and ongoing, expanding the scope of possible treatment options for precursor diseases.
PMID:38724285 | DOI:10.1016/j.hoc.2024.03.003